Background
==========

Treatment with X-radiation (XR) remains a major modality for eradicating cancer and it has been estimated that half of all cancer patients undergo radiotherapy at some point during their treatment \[[@B1]\]. At least partly because of the relevance of radiotherapy to cancer treatment, the genetic control of the expression of resistance, or conversely, sensitivity to XR has been investigated for several decades. It is now generally accepted that there are several components to the cellular response to XR stress: sensing of the DNA damage, cell signaling pathways, and repair of the DNA damage \[[@B2]\]. However, the molecular mechanisms of how cells detect, communicate, and cope with XR-induced DNA damage are not well characterized. There is strong evidence that ataxia telangiectasia mutated (ATM) protein act as damage sensors and that their activation initiates mobilization and/or activation of repair complexes \[[@B3]\]. In addition, the ATM kinase activity mediates the prompt induction of various signaling pathways with some of these events leading to either cellular apoptosis or cell cycle arrest \[[@B4]\]. There is also evidence that non-homologous end joining involving Ku86/Ku70 is likely the major DNA double strand breaks rejoining pathway following XR with a smaller role for homologous recombination in post replicated DNA \[[@B5]\].

Many of the studies on the genetic basis of cellular response to XR have benefited either from mutants that have increased ionizing radiation (IR) sensitivity compared to the parental cell lines or from the study of human genetic syndromes that are associated with increased IR sensitivity (i.e. Fanconi\'s anemia, Bloom\'s, and Werner\'s syndromes) \[[@B6],[@B7]\]. By contrast, mutants or human genetic syndromes associated with increased IR resistance (as exemplified by Li Fraumeni) are rare \[[@B8]\]. Furthermore, Bennett et al \[[@B9]\] recently identified 107 new loci that are associated with response to γ-radiation in yeast. While over 50% of these newly identified putative yeast genes shared homology with human genes, it remains to be established that the human counterparts of these genes are actually associated with similar responses to γ-radiation.

In order to further investigate the genetic basis of tumor cell radioresponse, we have isolated several clones with a wide range of responses to X-radiation from an unirradiated human colorectal tumor cell line, HCT116. Interestingly, we found a cell clone, HCT116^Clone2_XRR^that was resistant to both fractionated and single dose X-radiation when compared to the parental cells. In addition, we also isolated two other clones: (a) HCT116^CloneK_XRS^that was more sensitive than the parental cells, and (b) HCT116^Clone10^that possessed similar X-radiation responses as the parental cells, to both of these types of X-radiation (Qutob, S.S., Ng, C.E., to be published elsewhere). Global gene analysis between cells HCT116^Clone2_XRR^and HCT116^Clone10^using cDNA microarray identified an unknown GenBank expression sequence tag (EST) accession no. R40588, as one of the spots on the 19,200 human cDNA microarray (University Health Network, Ontario Cancer Institute, Toronto), that was down regulated by approximately two-fold in HCT116^Clone2_XRR^in comparison with HCT116^Clone10^cells (Qutob, S.S., Ng, C.E., to be published elsewhere).

Here we describe the *in silico*analysis of R40588 that resulted in the identification of a novel gene, *XRRA1*. We cloned the *XRRA1*full-length cDNA from macaque testis and an *XRRA1*splice variant from HCT116^Clone2_XRR^cells. We then extended our analysis to identify *XRRA1*in several mammals (i.e. mouse, rat, pig and bovine). This paper also reports the experiments to evaluate *XRRA1*expression in human and macaque normal tissue/organs and in various human cancer and normal cell lines, as well as over-expression of GFP-XRRA1 fusion protein in HCT116 clones and COS-7 cells. We did immunostaining of Ku86 in the presence of over-expressed GFP-XRRA1 24 hours after XR treatment at 4 and 10 Gy of COS-7 cells. This is the first report on the molecular cloning, genomic characterization and over-expression of the novel *XRRA1*gene.

Results
=======

Genomic approaches revealed a novel *XRRA1*gene
-----------------------------------------------

Using the EST sequence of R40588 as template, we performed ESTs \"walking\" either towards the 5\' or 3\' direction on both the sense and anti-sense strands that we refer to as ESTs-based ORF assembling (EBOA). By EBOA, we acquired a cDNA candidate that putatively contained start-, stop-codon and poly-A signal. ESTs that overlapped each other sequentially were as follows: GenBank accession nos R40588, BQ648278, BU187847, BE782795, BI819448, BQ925455, and BM563944. Out of this ORF candidate, we found 31 ESTs as primary sequences that could be constructed into one potential novel gene *in silico*(Table [1](#T1){ref-type="table"}, Fig. [1](#F1){ref-type="fig"}). We have named this gene as X-ray radiation resistance associated 1 (*XRRA1*) (GenBank accession no. BK000541). BLAST \[[@B10]\] analysis demonstrated that it was a novel gene.

###### 

ESTs that were used to build Hs *XRRA1*and Mm *Xrra1*.

  **Organism**                    **EST**                 **Nucleotides**            **Exons**        **Genomic Clone**   **Exons**
  ------------------------------- ----------------------- -------------------------- ---------------- ------------------- -----------
  *Homo sapiens XRRA1*(1987 nt)   1\. BM563944.1          1 -- 822                   1 -- 7           AP001992.4          1 -- 5
                                  2\. BE780143.1          1 -- 233                   1 -- 2           AP000560.4          3 -- 11
                                  3\. AW962535.1          1 -- 175                   1 -- 2           AP001324.4          5 -- 11
                                  4\. BM921116.1          1 -- 107                   1                                    
                                  5\. BQ925455.1          1 -- 348, 513 -- 1066      1 -- 3, 4 -- 7                       
                                  6\. AI651142.1 (+/-)    225 -- 348, 513 -- 726     2 -- 3, 4 -- 6                       
                                  7\. AW448937.1 (+/-)    234 -- 348, 513 -- 726     2 -- 3, 4 -- 6                       
                                  8\. AI651143.1 (+/-)    245 -- 348, 513 -- 726     2 -- 3, 4 -- 6                       
                                  9\. AW197451.1 (+/-)    270 -- 348, 513 -- 726     2 -- 3, 4 -- 6                       
                                  10\. AW895676.1 (+/-)   513--609                   4 -- 5                               
                                  11\. BE836017.1 (+/-)   513 -- 609                 4 -- 5                               
                                  12\. BF810439.1         513 -- 589                 4 -- 5                               
                                  13\. AI652186.1 (+/-)   526 -- 726                 5 -- 6                               
                                  14\. BE313013.1         583 -- 1190                5 -- 8                               
                                  15\. BF891539.1 (+/-)   607 -- 694                 5 -- 6                               
                                  16\. BI819118.1         897 -- 1755                7 -- 11                              
                                  17\. BQ319609.1         1271 -- 1388               8 -- 10                              
                                  18\. BU620818.1 (+/-)   1275 -- 1976               9 -- 11                              
                                  19\. BU620757.1 (+/-)   1312 -- 1911               9 -- 11                              
                                  20\. AI057634.1         1474 -- 1981               10 -- 11                             
                                  21\. BQ051594.1         1492 -- 1979               10 -- 11                             
                                  22\. BE782795.1         1500 -- 1898, 1939--1987   11                                   
                                  23\. AW189295.1         1502 -- 1979               11                                   
                                  24\. AI655334.1         1546 -- 1976               11                                   
                                  25\. AA854636.1         1556 -- 1981               11                                   
                                  26\. AI218588.1         1593 -- 1979               11                                   
                                  27\. AI457916.1         1594 -- 1981               11                                   
                                  28\. AW513519.1 (+/-)   1614 -- 1758               11                                   
                                  29\. AA961245.1 (+/-)   1680 -- 1977               11                                   
                                  30\. BU187847.1         1796 -- 1987               11                                   
                                  31\. AA953084.1 (+/-)   1845 -- 1977               11                                   
  *Mus musculus Xrra1*(1903 nt)   1\. BI990168.1          277 -- 870                 2 -- 7           NW_000328           1 -- 11
                                  2\. AV046823.1          715 -- 978                 6 -- 7                               
                                  3\. BE650319.1          857 -- 1380                7 -- 9                               
                                  4\. BU610007.1          1134 -- 1459               8 -- 10                              
                                  5\. AA144723.1          1144 -- 1396               8 -- 10                              
                                  6\. AI647383.1          1184 -- 1372               8 -- 9                               
                                  7\. BE956083.1 (+/-)    1381 -- 1903               9 -- 11                              
                                  8\. BQ840215.1          1398 -- 1649               10 -- 11                             
                                  9\. BE631695.1          1458 -- 1604               10 -- 11                             
                                  10\. BQ175761.1 (+/-)   1458 -- 1903               10 -- 11                             
                                  11\. BE956870.1 (+/-)   1471 -- 1903               10 -- 11                             
                                  12\. AI449753.1 (+/-)   1600 -- 1901               11                                   
                                  13\. AW125246.1 (+/-)   1704 -- 1903               11                                   

![Human *XRRA1*cDNA sequences and its translation. The gene comprises 11 exons, and produces 559 aa protein. XRRA1 protein consists several motifs i.e. leucine rich repeats, PEST sequence, nuclear localization signal, and two sites of tyrosine phosphorylation (\*). Poly A-signal, AATAA is underlined.](1471-2164-4-32-1){#F1}

We used human genomic clones RP11-147I3 and CMB9-8M21 (GenBank accession nos AP001992 and AP000560) of chromosome 11q13.3 as template for GrailEXP \[[@B11]\] analysis. The analysis predicted 11 exons including a putative promoter region for the human (*Homo sapiens*, Hs) *XRRA1*gene (Fig. [2](#F2){ref-type="fig"}, Fig. [3A](#F3){ref-type="fig"}). These 11 exons spliced perfectly to create the mRNA for Hs *XRRA1*. The exon-intron junctions, comprising the 5\' splice donor and 3\' splice acceptor, follow Kozak consensus (Table [3](#T3){ref-type="table"}) \[[@B12]\]. Cloning of the 5\' region of *XRRA1*gene that comprised the first four exons from HCT116^Clone2_XRR^and HCT116^Clone10^revealed that Hs *XRRA1*had those exons. However, in addition to the one from HCT116^Clone2_XRR^, we obtained one splice variant that lacked exon three and ended on exon four (GenBank accession no. AY163836) (Fig. [3A](#F3){ref-type="fig"}).

![Promoter region of human *XRRA1*gene as predicted by GrailExp \[[@B11]\]. Two putative sites of TATA box were found at -506 and -400 from the start codon. Predicted transcription factor binding sites revealed several members of bZIP family such as C/EBPa, c-Jun, c-Fos, AP-1 and CREB.](1471-2164-4-32-2){#F2}

![Representation of the *XRRA1*genomic structure. (A) The *XRRA1*gene spans 64 kb and comprises 11 exons. HCT116^Clone2_XRR^cells contain 2 splice variants, one of which lacks exon 3 and is truncated. Other cDNA clones such as BC032794 lack exon 4, AK074152 lacks exon 3--4 and possible partial deletion of exon 5, and AK056364 lacks exon 2--4 and 10. The gene is located between genomic markers D11S916-D11S911 (80.1--84.2 cM) or at position 625.9 cR of NCBI RH Map. (B) The assembled Hs *XRRA1*comprises a putative promoter region, start/stop codons and poly-A signal, and predicted a protein with motifs such as LRR, PEST, and NLS. Scale bar is multiplied by 100.](1471-2164-4-32-3){#F3}

To test whether these exon-intron borders were actually unique to *XRRA1*, we searched for possible *XRRA1*homologues from other organisms. Thus far, we could only retrieve *Xrra1*containing genomic clones from mouse (*Mus musculus*, Mm) (GenBank accession no. NW_000328) and rat (*Rattus norvegicus*, Rn) (GenBank accession no. AC127923). Mm *Xrra1*gene is located on chromosome 7. GrailEXP analyses showed that Mm *Xrra1*gene also contained 11 exons. Alignment of mouse and rat genomic sequences resulted in information for rat exons, which also consist of 11 exons. Interestingly, all the exon-intron borders of Hs *XRRA1*, Mm and Rn *Xrra1*genes are well conserved (Table [3](#T3){ref-type="table"}). We again employed EBOA to look for all possible ESTs of mouse and other organisms (Table [2](#T2){ref-type="table"}). We used the longest human EST containing *XRRA1*cDNA sequence as template for the analysis. From the mouse dbEST, we obtained 13 ESTs as primary sequences, which assembled Mm *Xrra1*(GenBank accession no. BK000542). However, unlike the GrailEXP analysis, Mm *Xrra1*lacks exon one and part of exon two. Nevertheless, these two approaches verified the cDNA sequence for Mm *Xrra1*. We could not find any publicly available ESTs for rat. Other ESTs found to be homologues to *XRRA1*were from pig (*Sus scrofa*, Sc), horse (*Equus caballus*, Eq) and bovine (*Bos taurus*, Bt). We assembled Bovine (Bt) *Xrra1*(GenBank accession no. BK000644) from 5 ESTs. The Bt *Xrra1*gene is likely to have 11 exons with truncated exons 4 and 8 (Table [2](#T2){ref-type="table"}, Fig. [3A](#F3){ref-type="fig"}).

###### 

ESTs of Mm, Rn, Bt, Sc, and Eq *Xrra1*with corresponding nucleotides and exons to Hs *XRRA1*

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Organism**                     **EST**            **Corresponding Nucleotides of Hs *XRRA1***            **Corresponding Exons of Hs *XRRA1***   **Genomic Clone**   **Exons**
  -------------------------------- ------------------ ------------------------------------------------------ --------------------------------------- ------------------- -----------
  *Mus musculus Xrra1*(1903 nt)    BI990168.1         312 -- 776                                             2 -- 7                                  NW_000328           1 -- 11

                                   AV046823.1         660 -- 1011                                            6 -- 7                                                      

                                   BE650319.1         1017 -- 1093, 1215--1414                               7 -- 8, 8 -- 10                                             

                                   BU610007.1         1215 -- 1383, 1400 -- 1491                             8 -- 9, 10                                                  

                                   AA144723.1         1215 -- 1414                                           8 -- 10                                                     

                                   AI647383.1         1215 -- 1383, 1400 -- 1491                             8 -- 9, 10                                                  

                                   BE956870.1 (+/-)   1437 -- 1491, 1529 -- 1599, 1668 -- 1737, 1933--1966   10, 11                                                      

                                   BQ840215.1         1436 -- 1599                                           10 -- 11                                                    

                                   BE631695.1         1529 -- 1599                                           11                                                          

                                   BQ175761.1 (+/-)   1529 -- 1599, 1668 -- 1737, 1933 -- 1966               11                                                          

                                   BE956083.1 (+/-)   1529 -- 1599, 1668 -- 1737, 1933 -- 1966               11                                                          

                                   AI449753.1 (+/-)   1668 -- 1737, 1933 -- 1966                             11                                                          

                                   AW125246.1 (+/-)   1933 -- 1966                                           11                                                          

  Rattus norvegicus *Xrra1*\                                                                                                                         AC127923.2          1 -- 11
  (1909 nt)                                                                                                                                                              

  *Bos taurus Xrra1*\              BM106446.1         1 -- 422                                               1 -- 4                                                      
  (1759 nt)                                                                                                                                                              

                                   BI540915.1         542 -- 703                                             5 -- 6                                                      

                                   BE722755.1         797 -- 1248                                            7 -- 8                                                      

                                   BM254248.1         1308 -- 1760                                           9 -- 11                                                     

                                   BE751905.1         1366 -- 1761                                           9 -- 11                                                     

  *Sus scrofa Xrra1*(970 nt)       BF442510.1         407 -- 708                                             4 -- 6                                                      

                                   BF442490.1         407 -- 703                                             4 -- 6                                                      

                                   BF444411.1         407 -- 514, 1208 -- 1269                               4, 8 -- 9                                                   

                                   BI341438.1         581 -- 810, 877 -- 978, 1006 -- 1079                   5 -- 7, 7, 7 -- 8                                           

  *Equus caballus Xrra1*(621 nt)   BM735121.1         1336 -- 1575, 1658 -- 1761, 1902 -- 1970               9 -- 11, 11, 11                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Exon-intron junctions of human (Hs) *XRRA1*, murine (Mm) *Xrra1*and rat (Rn) *Xrra1*

  **Exon No.**                **Exon Size (bp)**   **5\' Splice Donor**                **Intron No.**   **Intron Size (bp)^a^**   **3\' Splice Acceptor**
  -------------- ------------ -------------------- ----------------------------------- ---------------- ------------------------- -----------------------------------
  1              Hs *XRRA1*   128                  GGCTCAGGAG**[gt]{.ul}**aaagccataa                                              ttgcactcac**[ag]{.ul}**GGAGGCATCT
                 Mm *Xrra1*   133                  GGCTCAGGAG**[gt]{.ul}**attgtcacag                                              ctgtgcccac**[ag]{.ul}**GGAGGCATCC
                 Rn *Xrra1*   133                  GGCTCAGGAG**[gt]{.ul}**attatcacag                                              ctgtgcccac**[ag]{.ul}**GGAGGCATCT
  2              Hs *XRRA1*   219                  GACCGGACAG**[gt]{.ul}**gagtgacacc   1                687                       ccttaattga**[ag]{.ul}**ACTGAAGAAG
                 Mm *Xrra1*   206                  GACCGCACAG**[gt]{.ul}**gagctatggc                    685                       ccttaattga**[ag]{.ul}**ACTGAAGAAG
                 Rn *Xrra1*   206                  GACCGCACAG**[gt]{.ul}**gagcccgccc                    \-                        tcttaattga**[ag]{.ul}**ACTGAAGAAG
  3              Hs *XRRA1*   43                   AACCTCAGAG**[gt]{.ul}**aggaactgac   2                43215                     cttctgtttc**[ag]{.ul}**AGGTTGTGTT
                 Mm *Xrra1*   44                   AACCTCAGAG**[gt]{.ul}**aggaggacct                    4118                      tttctgtttc**[ag]{.ul}**AGGTTGTGTT
                 Rn *Xrra1*   44                   AACCTCAGAG**[gt]{.ul}**aggaggaacc                    \-                        tttatgtttc**[ag]{.ul}**AGGTTGTGTT
  4              Hs *XRRA1*   127                  CTACAACAAG**[gt]{.ul}**gactttctgc   3                3696                      cttctttcta**[ag]{.ul}**ACAACCAAGA
                 Mm *Xrra1*   126                  CTACAACAAG**[gt]{.ul}**aactgctttg                    3706                      tttcctctga**[ag]{.ul}**ACAGCCAAGG
                 Rn *Xrra1*   126                  CTACAACAAG**[gt]{.ul}**aaactgcttt                    \-                        ttccctccta**[ag]{.ul}**ACAACCAAGG
  5              Hs *XRRA1*   96                   CATACACGAG**[gt]{.ul}**atagtgcccg   4                7073                      cattcattag**[ag]{.ul}**ATCGCAAAAG
                 Mm *Xrra1*   94                   CACACACGAG**[gt]{.ul}**atggtggcca                    4393                      cattcattag**[ag]{.ul}**ATCGCAAAAG
                 Rn Xrra1     94                   CACACACGAG**[gt]{.ul}**atggtggcca                    \-                        tgcactttcc**[ag]{.ul}**ATCGCAAAGG
  6              Hs *XRRA1*   123                  ATCATGGAAG**[gt]{.ul}**agggcttcca   5                779                       tcatggcacc**[ag]{.ul}**GGGTCCCTCC
                 Mm *Xrra1*   116                  GTCACGGAAG**[gt]{.ul}**aagccttcca                    736                       ccttcatacc**[ag]{.ul}**GGATCCACAC
                 Rn *Xrra1*   116                  ATCGCGGAAG**[gt]{.ul}**aagccttcca                    \-                        ccctcacacc**[ag]{.ul}**GGATCCCACC
  7              Hs *XRRA1*   351                  CCTGACCCAG**[gt]{.ul}**acctgtatcc   6                2622                      tctccatgac**[ag]{.ul}**GTGAAAAGCG
                 Mm *Xrra1*   324                  CCTGACCCAG**[gt]{.ul}**gacagccccc                    2256                      tctctcatcc**[ag]{.ul}**GTGAAGACCT
                 Rn *Xrra1*   324                  CCTGACCCAG**[gt]{.ul}**gacagccccc                    \-                        tctctcatac**[ag]{.ul}**GTGAAAACCT
  8              Hs *XRRA1*   202                  GAGCCAAAGG**[gt]{.ul}**atgtgagggc   7                2839                      tcctgggcac**[ag]{.ul}**GTGAGTGAAC
                 Mm *Xrra1*   196                  GAGCCAAAGG**[gt]{.ul}**atgggattaa                    1421                      ttcctggcac**[ag]{.ul}**GTGAATGAGC
                 Rn *Xrra1*   199                  GAGCCAAAGG**[gt]{.ul}**acgggattaa                    \-                        ttcctggcac**[ag]{.ul}**GTGAATGAGC
  9              Hs *XRRA1*   117                  AGAGAAACGG**[gt]{.ul}**aaacatccag   8                788                       ttcttgccct**[ag]{.ul}**GGAATCCAGA
                 Mm *Xrra1*   116                  GGAGAAGAGG**[gt]{.ul}**aagcacttca                    594                       tgcatcctct**[ag]{.ul}**GCATCCAGAA
                 Rn *Xrra1*   116                  AGAGAAGAGG**[gt]{.ul}**aagcacttca                    \-                        tgcatcctcc**[ag]{.ul}**GCATCCAGAA
  10             Hs *XRRA1*   108                  GCTCCACTAG**[gt]{.ul}**acggctctgc   9                207                       accttctgcc**[ag]{.ul}**GCCCAGAGAA
                 Mm *Xrra1*   106                  GCTCCACTGG**[gt]{.ul}**atggtgccag                    169                       tgcatcctct**[ag]{.ul}**GCCGGGAGGA
                 Rn *Xrra1*   106                  GCTCCACTGG**[gt]{.ul}**atggtgccag                    \-                        cgtttgtgcc**[ag]{.ul}**GTTGCGAGGA
  11             Hs *XRRA1*   484                                                      10               397                       cttttcctgc**[ag]{.ul}**GTGCTGTCCT
                 Mm *Xrra1*   445                                                                       294                       tcattcctgt**[ag]{.ul}**GCACTGTGTT
                 Rn *Xrra1*   445                                                                       \-                        tcatccctgt**[ag]{.ul}**GCGCTGTGTG

^a^The intron sizes of Rn *Xrra1*gene could not be determined since the sequencing of rat genomic clone CH230-188L13 (GenBank AC127923) containing the gene was in progress. Nevertheless, their splicing sites can be identified, thus the exon sizes are also known.

We used cDNA libraries from macaque (*Macaca fascicularis*, Mf) brain and testis to obtain Mf *XRRA1*. Since we have created and sequenced these libraries, we were able to look for the Mf *XRRA1*. We found only three testis clones (QtsA-12093, 10089 and 20433) from 10,400 testis and 53,000 brain cDNAs that were homologous to Hs *XRRA1*. One of the clones, QtsA-20433 (GenBank accession no. AB072776) had the full-coding sequence and showed strong identity to Hs *XRRA1*, sharing 96 and 95% identities in cDNA and protein sequences, respectively. SIM4 \[[@B13]\] and BLAST analysis showed that Mf *XRRA1*sequence dispersed properly into 11 exons on human chromosomal band 11q13 (Fig. [3A](#F3){ref-type="fig"}).

*XRRA1*is conserved among human, macaque, mouse, rat, pig and bovine
--------------------------------------------------------------------

Multiple alignments of both *XRRA1*cDNA and protein sequence from human, macaque, mouse, rat, pig, and bovine *Xrra1*s showed a conservative molecule. Percent identities at both the nucleotide and protein level among these mammals resulting from two by two alignments are listed in Table [4](#T4){ref-type="table"}. As expected, phylogenetically, human *XRRA1*is closer to macaque *XRRA1*and both of them are closer to bovine and pig *Xrra1*s than murine and rat *Xrra1*s. We failed to find possible *XRRA1*homologues in other organisms ranging from microorganisms, plants, and animals. The latter included organisms whose genomes have been sequenced completely such as yeast, plasmodium, fruit fly, zebra fish and fugu.

###### 

Percent identities of *XRRA1*cDNA and protein among several mammals

                **Percent Identity (cDNA)\***                                                       
  -- ---------- ------------------------------- ------------ ------------ ------------ ------------ ------------
     HsXRRA1    \-                              ***96.0***   ***75.9***   ***75.9***   ***83.4***   ***76.8***
     Mf XRRA1   95.0                            \-           ***76.2***   ***76.3***   ***83.6***   ***77.2***
     MmXrra1    71.8                            74.1         \-           ***93.6***   ***74.6***   ***70.9***
     Rn Xrra1   69.6                            71.7         90.2         \-           ***74.7***   ***70.1***
     Sc Xrra1   77.7                            79.4         67.7         62.6         \-           ***86.4***
     Bt Xrra1   68.3                            69.5         62.0         61.6         70.1         \-

\*Hs, *Homo sapiens*; Mf, *Macaque fascicularis*; Mm, *Mus musculus*; Rn, *Rattus norvegicus*; Sc, *Sus scrofa*; Bt, *Bos taurus*.

The Hs *XRRA1*gene produces a novel 559 aa protein (Fig. [3B](#F3){ref-type="fig"}). The XRRA1 protein contains two possible sites of leucine-rich repeats (aa 20--41 and aa 138--164), a PEST sequence at aa 247--264, two tyrosine phosphorylation sites at aa 81 and aa 142, and bipartite nuclear targeting sequences are found at aa 357--373 and aa 485--501. Besides human, Mf XRRA1, Mm, Rn, and Bt Xrra1s retain the above-mentioned motifs.

*XRRA1*responded differentially to XR in clones of varying radiation responses
------------------------------------------------------------------------------

The RT-PCR results confirmed earlier observation from our cDNA microarray analysis that unirradiated HCT116^Clone2_XRR^cells had lower basal expression of *XRRA1*than unirradiated HCT116^Clone10^cells (Fig. [4](#F4){ref-type="fig"}, Table [5](#T5){ref-type="table"}). However, *XRRA1*expression in HCT116^Clone2_XRR^cells increased almost immediately (\~10 minutes) after XR and decreased thereafter. By contrast, HCT116^Clone10^cells down regulated *XRRA1*expression approximately ten minutes following XR. Interestingly, *XRRA1*expression in HCT116^CloneK_XRS^cells was initially similar to HCT116^Clone10^cells but regained the basal levels by 24 hours following XR.

![RT-PCR of *XRRA1*and a house-keeping gene *G3PDH*from HCT116 clones treated with X-radiation, various cancer and normal cells, and normal tissues/organs. The same set of primers was used to amplify corresponding mRNA from mouse embryonic stem cells and fibrosarcoma cells/tumor.](1471-2164-4-32-4){#F4}

###### 

Differential expression of human *XRRA1*in XR-treated HCT116 clones, in normal tissues/organs and cells, as well as in various cancer cell types.

  **Cells/Tissues/Organs**   **Relative Expression Level (Normalized against *G3PDH*)\***   **Cell/Tissue/Organ type; Cancer Type**
  -------------------------- -------------------------------------------------------------- -------------------------------------------------------
  HCT116^Clone2_XRR^         +++                                                            Colorectal, more resistant to X-radiation than HCT116
  HCT116^Clone10^            ++++                                                           Colorectal, similar radiation response to HCT116
  HCT116^CloneK_XRS^         ++++++                                                         Colorectal, more sensitive to X-radiation than HCT116
  HCT116^Clone2_XRR^         +++                                                            Without X-radiation
  HCT116^Clone2_XRR^M10      ++++                                                           10 Minutes after X-radiation
  HCT116^Clone2_XRR^H6       ++                                                             6 Hours after X-radiation
  HCT116^Clone2_XRR^H24      \+                                                             24 Hours after X-radiation
  HCT116^Clone10^            ++++                                                           Without X-radiation
  HCT116^Clone10^M10         \+                                                             10 Minutes after X-radiation
  HCT116^Clone10^H6          \+                                                             6 Hours after X-radiation
  HCT116^Clone10^H24         \+                                                             24 Hours after X-radiation
  HCT116^CloneK_XRS^         ++++++                                                         Without X-radiation
  HCT116^CloneK_XRS^M10      \+                                                             10 Minutes after X-radiation
  HCT116^CloneK_XRS^H6       \+                                                             6 Hours after X-radiation
  HCT116^CloneK_XRS^H24      ++++                                                           24 Hours after X-radiation
  Testis                     ++++++++                                                       Normal
  Prostate                   +++++                                                          Normal
  Ovary                      +++++                                                          Normal
  Leukocyte                  ++                                                             Normal
  Spleen                     \+                                                             Normal
  Thymus                     ++                                                             Normal
  Small Intestine            ++                                                             Normal
  Colon                      \+                                                             Normal
  AG1522                     ++++                                                           Normal fibroblast (immortalized)
  COS-7                      +++                                                            Normal fibroblast (immortalized)
  HDMEC                      ++++                                                           Normal microvascular endothelial (primary)
  MCF7                       \+                                                             Breast cancer
  MDA MB435                  +++++                                                          Breast cancer
  U251MG                     \+                                                             Glioma
  SKMEL-3                    \+                                                             Melanoma
  HT144                      \+                                                             Melanoma
  HTB56                      +++                                                            Lung cancer
  A594                       ++++                                                           Lung cancer
  Daoy                       ++++                                                           Neuroblastoma
  SKNA                       +++                                                            Neuroblastoma
  SHSY                       ++++                                                           Neuroblastoma
  A2780CP                    \+                                                             Ovarian cancer, resistant to cisplatin
  OCCL                       ++++                                                           Ovarian cancer
  OV2008                     ++++                                                           Ovarian cancer
  C13                        +++                                                            Ovarian cancer
  433                        \+                                                             Ovarian cancer
  SKOV3                      ++                                                             Ovarian cancer
  HEY                        ++++                                                           Ovarian cancer
  429                        +++                                                            Ovarian cancer
  PC-3                       \+                                                             Prostate cancer
  DU145                      +++++                                                          Prostate cancer
  SN12C                      \+                                                             Renal cancer
  HT29                       \+                                                             Colorectal cancer
  K-562                      +++++                                                          Leukemia
  Mm TM28                    +++                                                            (Murine) Fibrosarcoma
  Mm FS-TM28                 \+                                                             (Murine) Fibrosarcoma biopsy
  Mm ES-R1                   ++                                                             (Murine) Embryonic Stem Cell

\*+, very low; ++, low; +++ moderate; \>++++, high.

*XRRA1*was expressed predominantly in the testis in human and macaque
---------------------------------------------------------------------

We carried out DNA microarray where PCR-amplified QtsA-20433 (Mf *XRRA1*) was included. Because we found that Mf *XRRA1*was more commonly present in testis than in brain cDNA libraries, we further investigated whether Mf *XRRA1*was predominantly expressed in the testis. The ratio of Mf *XRRA1*expression in testis to that in mixed tissues was 3.02. We also compared the expression of *XRRA1*between human and macaque testis. The ratio of *XRRA1*expression in human testis to macaque testis was 1.04. In addition, we examined Hs *XRRA1*expression from various normal human tissues/organs. We found that Hs *XRRA1*was expressed predominantly in testis followed by prostate and ovary (Fig. [4](#F4){ref-type="fig"}, Table [5](#T5){ref-type="table"}). Other tissues/organs such as peripheral blood leukocyte, spleen, thymus, small intestine and colon demonstrated low expression of Hs *XRRA1*.

*XRRA1*was expressed ubiquitously in various types of cancer cells
------------------------------------------------------------------

We evaluated the expression of Hs *XRRA1*in various cancer cell lines (neuroblastoma, glioma, breast, lung, leukemia, renal, ovarian, prostate, another colorectal). *XRRA1*was present in all of those cells, although the expression level was variable (Fig. [4](#F4){ref-type="fig"}, Table [5](#T5){ref-type="table"}). We also detected *XRRA1*expression in immortalized normal fibroblast AG1522 and COS-7 cells, as well as in a dermal microvascular endothelial cell line (HDMEC). Surprisingly, besides mouse fibrosarcoma cells and tumor biopsy from a mouse model of fibrosarcoma, we were also able to detect Mm *Xrra1*expression in pluripotent cells such as murine embryonic stem cells R1 (Fig. [4](#F4){ref-type="fig"}, Table [5](#T5){ref-type="table"}).

Over-expression of GFP-XRRA1 fusion protein was only achieved transiently and showed nucleo-cytoplasmic protein distribution
----------------------------------------------------------------------------------------------------------------------------

To understand further the possible function of the *XRRA1*gene, we fused the *XRRA1*cDNA immediately downstream of a green fluorescent protein (*GFP*) cDNA. We over-expressed the GFP-XRRA1 in HCT116 clones, but after 48 hours post-transfection the fluorescence clearly decreased both in the number of cells and intensity of fluorescence. We obtained similar results when we over-expressed GFP-XRRA1 in COS-7 cells. After three weeks selection in 500 μg/ml G418, very few COS-7 cells remained fluorescent (Fig. [5](#F5){ref-type="fig"}). Only transient expression of the GFP-XRRA1 was observed in both types of cells. The fluorescence of the GFP-XRRA1 did not show an exclusive nuclear localization (although the predicted XRRA1 protein contains NLS motif). Instead, the fluorescence appeared in most cells to be nucleo-cytoplasmic (Fig. [5](#F5){ref-type="fig"}).

![GFP-XRRA1 fusion protein in COS-7 and HCT116 clones. A, B, and C are transfected COS-7 cells. D, E, and F are transfected HCT116^Clone2_XRR^cells. Control with GFP cassette alone is on panel A and D. Expression of GFP-truncated XRRA1 is shown in panels B and E. Expression of GFP-full length XRRA1 is shown in panels C and F. Transfected COS-7 cells were examined by fluorescence microscopy after 3 weeks of G418-selection. Expression of GFP-XRRA1 fusion protein was detected only transiently in HCT116 clones. The leftmost panel is a phase-contrast picture of the cells. The middle panel is green fluorescence shown with FITC filter. The rightmost panel is an overlay of the two previous panels. Magnification used was 400×.](1471-2164-4-32-5){#F5}

Over-expressed COS-7 cells with GFP-XRRA1 might modulate Ku86 expression
------------------------------------------------------------------------

Ku86 was exclusively localized in nuclei with or without XR (Fig [6](#F6){ref-type="fig"}). The over-expression of GFP-XRRA1 abolished nuclear immunostaining of Ku86 in COS-7 (Fig [6A](#F6){ref-type="fig"}). Immunostaining of α-Tubulin, as additional control for the experiment, did not change in the presence of GFP-XRRA1 (Fig [6B](#F6){ref-type="fig"}). The secondary antibody conjugated with Cyanine-3 (Cy3) was used for both Ku86 and α-Tubulin immunostaining.

![Immunocytochemistry of COS-7 cells over-expressing GFP-XRRA1 with Ku86 (A) and α-Tubulin (B). (A) Ku86 (red fluorescence) was localized in nuclei. Nuclear Ku86 immunostaining was eliminated (asterisk) in the presence of GFP-XRRA1 (green fluorescence), but not with the GFP alone. (B) Neither GFP nor GFP-XRRA1 changed the immunostaining of α-Tubulin (red fluorescence). DAPI-stained nuclei are shown in blue fluorescence. Magnification used was 1000×.](1471-2164-4-32-6){#F6}

Discussion
==========

EBOA and *in silico*analysis helped us to identify a novel gene *XRRA1*from a previously unknown EST R40588 not only in human, but also in mouse, bovine, and rat. Recently, several clones that contained Hs *XRRA1*spliced variants have been deposited to GenBank database by others. Hs *XRRA1*clone from testis (GenBank accession no. BC037294) lacked exon 4; the one from spleen (GenBank accession no. AK074152) lacked exons 3, 4 and a possible partial deletion of exon 5, and the one from NT2 cells (GenBank accession no. AK056364) lacked exons 2, 3, 4, and 10 (Fig. [3A](#F3){ref-type="fig"}). The testis clone with GenBank no. BC037294 did not appear to have a proper open reading frame. EBOA and GrailExp methods failed to produce a start site further upstream of Hs *XRRA1*(GenBank no. BK000541).

Surprisingly, when we searched from approximately 63,400 macaque brain and testis cDNAs, we found only three testis clones that were homologous to Hs *XRRA1*, suggesting that the Mf *XRRA1*gene is expressed only at a very low level in brain. The Mf *XRRA1*is highly homologous with Hs *XRRA1*. Because the Hs *XRRA1*gene consists of 11 exons, it is likely that the Mf *XRRA1*gene also contains 11 exons (see Fig. [3A](#F3){ref-type="fig"}). In general, the *XRRA1*gene seems to be highly conserved among mammals (i.e. human, macaque, mouse, rat, pig, and bovine), suggesting that it has similar function(s). Moreover, we were unable to find any convincing evidence of *XRRA1*gene from fully sequenced genomic DNA of fish, fly, worm, yeast and microbes. This suggests that *XRRA1*might be specific for, or evolutionary-enriched in, mammals. A specific role(s) for *XRRA1*in mammals was further supported by the observation that the predicted protein sequences for motifs such as LRR, PEST, and NLS, as well as Tyr phosphorylation sites, are preserved among the above-mentioned mammals. Additionally, these motifs suggested that the *XRRA1*protein may interact dynamically with other proteins, or might be subjected to rapid degradation via the proteasomal pathway, or might suggest a possible role for *XRRA1*in cellular signaling.

Although the protein contains a NLS motif, it appears that XRRA1 is not exclusively located in the nucleus, as shown by the over-expression of the GFP-XRRA1 fusion protein. HCT116 clones and COS-7 cells containing the fusion protein (either with full length or truncated XRRA1 protein) had lost the auto-fluorescence. This suggested that the protein concentration above the basal expression levels of XRRA1 might be lethal to the cells.

It is noteworthy that the expression of *XRRA1*in HCT116 clones was variably affected by 4 Gy XR. The results suggested that the *XRRA1*gene might be involved in the immediate response following XR and might further be linked to XR resistance and/or sensitivity. Thus the return of *XRRA1*to almost pre-irradiated basal levels by 24 hours post-irradiation in radiosensitive HCT116^CloneK_XRS^cells (but not in the other two clones) might be necessary for the subsequent manifestation of enhanced sensitivity to XR by this clone. One possibility is that the *XRRA1*gene may play a role either in the expression of cell death and/or signaling of DNA damage following XR stress. Therefore, genetic modulation of the expression of *XRRA1*in these clones may, specifically lead to either enhanced or decreased XR-induced lethality, and, generally, may be relevant for determining cellular response to XR in both tumor and normal cells.

In mammalian cells, DNA double strand breaks caused by XR are preferentially repaired by non-homologous end joining (NHEJ) mechanism. The major molecules involved in the NHEJ pathway are heterodimeric DNA end-binding complexes Ku86/Ku70 \[[@B14]\]. Therefore, we used Ku86 as the first candidate to test whether XRRA1 is involved in the modulation of the NHEJ pathway. The immunocytochemistry study on both HCT116^Clone2_XRR^and COS-7 cells showed that there was no significant modulation of Ku86 with XR. However, COS-7 cells over-expressing GFP-XRRA1 were devoid of nuclear Ku86. This phenomenon suggested that over-expression of XRRA1 might have resulted in the down-regulation of Ku-86. Further studies are required to determine whether there is a negative correlation between XRRA1 and Ku86 expressions during cellular response to XR.

The varying expression of *XRRA1*following XR described above could be related to the role of transcription factors. In fact, we were able to detect a possible region between nt -506 and -400 from the start codon for transcription factor binding sites that regulate the expression of *XRRA1*. These factors were C/EBPα, HSF-1, c-Jun, c-Fos, AP-1, and CREB. Interestingly, most of the previously mentioned transcription factors are members of the bZIP superfamily. The latter is associated with various functions, including mediating G1 arrests \[[@B15],[@B16]\], regulating responses against environmental stresses including IR and UV \[[@B17]\], acting as an immediate-early response factor \[[@B18]\], controlling wide range plasticity processes \[[@B19]\], and serving as a promoter element that mediates transcriptional activation in response to increased levels of intracellular essential secondary messenger cAMP \[[@B20]\]. Thus, putative binding sites for these transcription factors further strengthen the suggestion that the expression of *XRRA1*was rapidly affected after XR treatment.

*XRRA1*was expressed predominantly in the testis in both human and macaque. It may be relevant to note that the testis is generally regarded as one of the most sensitive organs to XR \[[@B21]\]. Thus upregulation of *XRRA1*in an XR-sensitive organ would appear to be generally consistent with our observation that it is downregulated in the XR-resistant HCT116^Clone2_XRR^cells. Because there was comparable expression level of *XRRA1*in both human and macaque, it suggests that there is a functional necessity for *XRRA1*in mammalian testis (i.e. *XRRA1*might serve as a testis-specific molecule). By contrast, the low expression of *XRRA1*in healthy colon and relatively much stronger expression of *XRRA1*in HCT116 cells, may suggest an upregulation of this gene in cancer development. The ubiquitous expression of *XRRA1*in numerous cancer cells and in immortalized normal cells might be indicative of a role of this gene in tumor development.

Interestingly, from the SAGEmap, we identified three tags that specifically represent *XRRA1*anchored with restriction enzyme *Nla*III. The tags were TATTCAGGGG, ACCTGGTGCC, and GAATCAAGTG. SAGE libraries where *XRRA1*was less than 20 tags per million were excluded. We found that the *XRRA1*was present in mammary gland epithelium ductal *in situ*carcinoma, normal cerebellum, normal gastric body epithelium, well differentiated oligodendroglioma, pancreatic epithelium ductal adenocarcinoma, metastasis mammary gland carcinoma, ovarian clear cell poorly differentiated carcinoma, brain glioblastoma multiform cell line, ovarian serous adenocarcinoma, mammary gland ductal *in situ*high grade carcinoma, prostate carcinoma, brain juvenile ependymoma, and medulloblastoma cerebellum. The foregoing data further suggested that *XRRA1*might be correlated with carcinomas in breast, brain, prostate, pancreas and ovary. Finally, the expression of Mm *Xrra1*expression in mouse embryonic stem (ES) cells (R1) as well as in mouse fibrosarcoma cells and in fibrosarcoma biopsy suggest that *XRRA1*might function as an early expressed gene.

Conclusions
===========

*XRRA1*is a novel molecule that is expressed selectively in normal healthy tissues/organs. It is expressed at relatively higher levels in primary sex organs such as testis (of both human and macaque), prostate and ovary. The expression of *XRRA1*in normal proliferative cells, embryonic stem cells, and various tumor cells is also generally high and comparable to testicular expression of *XRRA1*. These findings suggest that *XRRA1*expression may be important for cell proliferation, development, and differentiation as well as carcinogenesis. In regard to XR, we found that *XRRA1*expression was rapidly modulated after treatment, suggesting the potential involvement of this gene/protein in the manifestation/expression of radioresistance/sensitivity by tumor cells such as human colorectal cancer cells. Over-expression of GFP-XRRA1 fusion protein was located in both nucleus and cytoplasm of HCT116 clones or COS-7 cells. A possible correlation with NHEJ pathway for repairing DNA double strand break after XR is shown by the lack of Ku86 immunostaining in COS-7 cells that over-expressed the GFP-XRRA1. Further experiments to determine the function of XRRA1 in DNA damage sensor, repair and apoptosis following radio- and or chemotherapy are ongoing. Also the function of XRRA1 in carcinogenesis as well as embryogenesis and reproduction biology needs to be elucidated.

Methods
=======

Normal/Cancer cell cultures
---------------------------

Clones of colorectal cancer cells (HCT116^Clone2_XRR^, HCT116^Clone10^, and HCT116^CloneK_XRS^), normal fibroblast cells (COS-7 and AG1522), breast cancer cells (MCF-7 and MDA MB435), glioma cells (U251 MG), melanoma cells (SKMEL-3 and HT144), lung cancer cells (HTB56 and A549), ovarian cancer cells (A2780CP and A2780S), prostate cancer cells (PC-3 and DU145), leukemia cells (K-562), colorectal cancer cells (HT29), renal cancer cells (SN12C), and mouse fibrosarcoma cells (TM28) were grown in DMEM/Ham\' s F12 1:1 mix (Wisent Inc., St. Bruno, QC, Canada) supplemented with 10% fetal bovine serum (FBS) (Wisent Inc.) and 15 mM HEPES in a humidified atmosphere of 95% air, 5% CO~2~at 37°C. Various individuals from the ORCC, Ottawa, Canada, kindly provided us with the cells. They were: J.C. Bell (COS-7, PC-3, DU145, K-562, HT29, and SN12C cells), C.L. Addison (MCF-7 and MDA MB435 cells, neuroblastoma cells (Daoy, SKNA, and SHSY), normal human dermal microvascular cells (HDMEC)), HC Birnboim (TM28 cells), B. Vanderhyden (ovarian cancer cells OCCL, OV2008, C13, SKOV3, 433, HEY, and 429), and M. McBurney (mouse embryonic stem cells R1). H.C. Birnboim also donated a C57BL/6 mouse with a solid fibrosarcoma (TM28) growing in the flank. A. Gatignon (Lady Davis Insitute, Montreal, Canada) kindly provided the U251 MG cells. Clones of HCT116, AG1522, SKMEL-3, HT144, A2780CP, and A2780S cells were from our own laboratory collection (C.E. Ng, ORCC, Ottawa, Canada).

Cloning and sequencing of Hs *XRRA1*splice variant
--------------------------------------------------

A specific primer pair was created to amplify the 5\' region of the *XRRA1*cDNA. They were 5\'-GCGCTGGAGACACTGATGCTGG ATGACAAC-3\' and 5\'-GGCCAGGCTAAGGTATCTCAGCTCTGGG-3\'. These primers generated a product of 452-bp that comprised the first 4 exons. Total RNA from HCT116^Clone2_XRR^and HCT116^Clone10^cells were used as template for RT-PCR. PCR fragments were gel purified using Gel Extraction Kit (Qiagen Inc., Mississauga, ON, Canada) and cloned into pTZ57R plasmid using InsT/Aclone PCR Product Cloning Kit (MBI Fermentas, Burlington, ON, Canada). Sequencing of the clones was performed by DNA Sequencer model 4000L according to the manufacturer\' s protocol (LI-COR Biosciences, Lincoln, NE, USA) using M13 primer.

Construction of macaque cDNA libraries and DNA sequencing of their cDNA inserts
-------------------------------------------------------------------------------

Oligo-capped cDNA libraries were made from macaque brain and testis. cDNAs were isolated according to the method described previously \[[@B22],[@B23]\]. The 5\'-end sequences of the clones were sequenced using ABI 3700 sequencer (Applied Biosystems, Tokyo, Japan) and categorized using DYNACLUST (Dynacom Co., Chiba, Japan) based on a BLAST search against the GenBank database. The entire sequences of clones were determined by the primer walking method with an ABI PRISM BigDye Terminator Sequencing kit (Applied Biosystems) according to the manufacturer\' s instructions.

Construction of plasmid expressing Mf XRRA1 fused to GFP
--------------------------------------------------------

Macaque cDNA clone of QtsA-20344 was found from the cDNA libraries to contain Mf *XRRA1*transcript. A 1709-bp *Xho*I fragment of Mf *XRRA1*was removed from pME18S-FL3 and sub-cloned into *Xho*I sites of pEGFP-C1 (BD Biosciences, Mississauga, ON, Canada), immediately downstream of the *GFP*sequence (pFM1709). To create a truncated Mf *GFP-XRRA1*(pFM584), 1.1-kb *Eco*RI fragment was removed from pFM1709 leaving a 584-bp of the 5\' *XRRA1*cDNA fused with *GFP*.

Transfection of *GFP-XRRA1*into HCT116^Clone2_XRR^, HCT116^Clone10^, HCT116^CloneK_XRS^, and COS-7 cells
--------------------------------------------------------------------------------------------------------

HCT116 clones and COS-7 cell were transfected with a mixture of pFM584, pFM1709 or pEGFP-C1 and lipid complexes FuGENE 6 (Roche Diagnostics, Laval, QC, Canada) transiently or stably. Briefly, HCT116 clones and COS-7 were grown on cover slips in a 6-well plate and reached 60--70% confluences before transfection. The ratio of FuGENE 6 and pure plasmid was 6:1 in serum free medium. G418 (Sigma-Aldrich, Oakville Ltd., ON, Canada) at a concentration of 400 μg/ml was used for selection. Cells were fixed with 3.7% formaldehyde in PBS for 10 min, and then washed three times with 1x PBS. Coverslips were mounted upside down onto slides with Dako Fluorescent Mounting Medium (DAKO, Carpinteria, CA, USA). Visualization was performed using a fluorescence microscope Axioskop 2 MOT (Carl Zeiss MicroImaging Inc., Thornwood, NY, USA). Images of cells were captured with a CCD camera fitted with a FITC filter.

Immunocytochemistry
-------------------

Transfected COS-7 and HCT116^Clone2_XRR^cells with pFM1709 or pEGFP-C1 were grown on cover slips until they reached 70--80% confluency before being treated with 4 or 10 Gy XR. Cells were fixed in 2% formaldehyde in 1x PBS for 15 min 24 h after XR treatment. Cells were then permeabilized with 0.2% Triton X-100 for 10 min. Ku86 antibody was obtained from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA. The secondary antibody was conjugated with Cy3 (Amersham Biosciences Corp, Baie d\' Urfe, QC, Canada). Controls for the immunostaining were the secondary antibody alone, and control for the experiment was α-Tubulin antibody that was obtained from Calbiochem, San Diego, CA, USA.

RT-PCR
------

Total RNAs of normal/cancer cells were extracted using RNAeasy kit (Qiagen Inc.) according to the manufacturer\' s instructions. TRIZOL Reagent (Invitrogen Inc., Burlington, ON, Canada) was used to isolate RNA of mouse fibrosarcoma tumor biopsy. RNAs of human peripheral blood leukocyte, spleen, thymus, small intestine, colon, ovary, testis and prostate were purchased from BD Biosciences. First Strand cDNA Synthesis kit (MBI Fermentas) was used to create first strand cDNA from RNA samples. A specific primer pair that amplified \~1 kb house keeping gene glyceraldehyde-3-phosphate dehydrogenase (*G3PDH*) was used as the control. The primers were 5\'-TGAAGGTCGGTGTGAACGGATTTGGC-3\' and 5\'-CATGTAGGCCA TGAGGTCCACCAC-3\'. Conditions of PCR were as follows: 94°C for 30 s, 61°C for 15 s, and 72°C for 40--60 s for 35 cycles. The PCR products were then separated on 1.5% agarose gels, stained with ethidium bromide, and visualized with the gel documentation imager Epi Chemi II (UVP Inc., Upland, CA, USA). Densitometry of bands were analyzed using Labworks™ software (UVP). Relative expression of *XRRA1*was calculated as percentages of the mean raw densities of grayscale level of *XRRA1*to *G3PDH*.

X-radiation of HCT116^Clone2_XRR^, HCT116^Clone10^, and HCT116^CloneK_XRS^cells
-------------------------------------------------------------------------------

Clones of HCT116 cells were cultured at 1 × 10^5^cells/ml. Cultures reached 70--80% confluence before being treated with XR. Each clone was treated with a single dose of 4 or 10 Gy using a 250 kVp X-ray unit (Pantak, CT, USA) at a dose rate of 150 cGy/min. Total RNAs were collected 5 minutes, 6 hours and 24 hours following the XR. Specific primers for Hs *XRRA1*as mentioned above were used. *G3PDH*was used as control. Relative expression of *XRRA1*to *G3PDH*was evaluated

cDNA microarray of Mf *XRRA1*from testis versus mixed tissues or human testis
-----------------------------------------------------------------------------

512 fully sequenced testis cDNA clones were amplified using 5\'-CTTCTGCTCTAAAAGCTGCG-\'3 as a forward primer and 5\'-CGACCTGCAGCTCGAGCACA-\'3 as a reverse primer. Successful amplification was confirmed by agarose gel electrophoresis. Approximately 300 μg /ml DNA in 2 × Solution-T reagent (Takara Bio Inc., Shiga, Japan) were printed on duplicate glass-slides with a GMS 417 arrayer (Genetic MicroSystems, Woburn, MA, USA). RNA was isolated with TRIZOL Reagent (Invitrogen K.K., Tokyo, Japan) and purified with Oligo-Tex (Takara Bio Inc.). Macaque testis RNA was labeled with Cy3-dUTP (Pharmacia K.K., Tokyo, Japan). A mixture of macaque RNA was also obtained from 10 tissues: brain, heart, skin, liver, spleen, renal, pancreas, stomach, small intestine, large intestine, and labeled with Cy5-dUTP (Pharmacia). We mixed equal amount of RNA of these ten tissues. In a separate experiment, RNA from human testis (BD Biosciences) was labeled with Cy5-dUTP. Both labeled RNAs were co-hybridized to DNA spots. After the hybridization and washing procedure, slides were scanned with ScanArray (PerkinElmer Life Sciences Co., Tokyo, Japan). Beta actin and/or total signal intensity was used as the control for hybridization. The methods and results of DNA microarray have been deposited in the Gene Expression Omnibus <http://www.ncbi.nlm.nih.gov/geo> with the accession numbers GPL206, GSM2387, and GSM2388.

ESTs-based ORF assembling (EBOA) and other *in silico*analysis
--------------------------------------------------------------

In order to elucidate what gene R40588 might represent, we employed EBOA to obtain the full-length cDNA containing start-, stop-codon, and poly-A signal or a complete open reading frame (ORF). The sequence of R40588 was used as a template to do BLAST search for all possible overlapping ESTs from human dbEST <http://www.ncbi.nlm.nih.gov/dbEST>. These retrieved ESTs, either sense-antisense or 5\'- and 3\'-direction, were selected and were again used as template for searching other overlapping ESTs. To confirm the ORF candidates, (i) we carried out a BLAST search against full-length cDNAs that were available on public databases, and (ii) genomic sequences comprising the ORF candidates were analyzed with GrailEXP version 3.3 <http://compbio.ornl.gov/grailexp>\[[@B11]\]. Multiple alignments were done according to ClustalW method \[[@B24]\]. Transcription factors and their binding sites were predicted by employing the Alibaba2 version 2.1 program <http://www.gene-regulation.com/pub/programs.html> that used the TRANSFAC database <http://transfac.gbf.de/TRANSFAC>\[[@B25]\]. Possible tissues/organs expression of *XRRA1*was explored from the SAGEmap <http://www.ncbi.nlm.nih.gov/SAGE>\[[@B26]\]. Protein motifs were searched using software available on these web sites: <http://www.expasy.ch/prosite>\[[@B27]\], <http://www.at.embnet.org/embnet/tools/bio/PESTfind>\[[@B28]\], and <http://www.cbs.dtu.dk/services/NetPhos>\[[@B29]\].

Data deposition
===============

The sequences reported in this paper have been deposited in the DDBJ/EMBL/GenBank databases under the accession numbers BK000541, AY163836, AB072776, BK000542, and BK000644, respectively. HUGO Gene Nomenclature Committee and MGD Nomenclature Committee have approved the names and symbols of the *XRRA1*and *Xrra1*genes.
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